Polar Asset Management Partners Inc. Buys New Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Polar Asset Management Partners Inc. purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the third quarter, according to its most recent filing with the SEC. The fund purchased 13,500 shares of the company's stock, valued at approximately $613,000.

A number of other institutional investors have also made changes to their positions in the company. Summit Securities Group LLC acquired a new position in Janux Therapeutics during the 2nd quarter valued at approximately $29,000. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in Janux Therapeutics during the 2nd quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after purchasing an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics during the 2nd quarter valued at approximately $151,000. 75.39% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 15,000 shares of the company's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the completion of the sale, the chief executive officer now owns 242,054 shares in the company, valued at approximately $16,217,618. This represents a 5.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the company's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $42.33, for a total value of $92,364.06. Following the sale, the insider now owns 7,000 shares of the company's stock, valued at approximately $296,310. This trade represents a 23.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 352,245 shares of company stock worth $17,032,336 over the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

JANX has been the subject of a number of analyst reports. Leerink Partners boosted their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a research report on Tuesday. Cantor Fitzgerald restated an "overweight" rating and set a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. BTIG Research boosted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Tuesday. Finally, Stifel Nicolaus boosted their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $79.90.

Janux Therapeutics Trading Down 2.0 %

Shares of Janux Therapeutics stock traded down $1.31 on Friday, reaching $64.99. 1,665,716 shares of the company were exchanged, compared to its average volume of 1,267,921. The firm has a market capitalization of $3.41 billion, a price-to-earnings ratio of -55.55 and a beta of 3.29. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $71.71. The stock has a fifty day moving average price of $50.98 and a 200-day moving average price of $46.22.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics's revenue for the quarter was down 82.6% compared to the same quarter last year. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.